drugset / Trial / NCT05379634

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634

Phase 2 Active not recruiting 36 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM).

Timeline

Start
2022-07-05
Primary completion
2025-09-04
Completion
2026-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Nipocalimab Monoclonal antibody Intravenous
Background Prednisone Other / unclassified Oral